InvestSMART

Control Bionics Limited (ASX:CBL)

ALERT: Price-sensitive ASX Announcement for CBL
Current share price for CBL : $0.059 -0.007 (-10.61%)+
Announcement
Release
31 Jul 2026 9:10AM
Price at Release
$0.066
Full Release
download
Summary
Control Bionics Limited, a non-invasive neurotechnology platform company, announced significant commercial progress across its strategic pillars of Assistive Technology and NeuroTechnology Solutions. The company has begun shipping its NextLevel tablets, marking a new revenue stream expected to drive growth in FY27. NeuroStrip, a wearable sEMG platform, has expanded to 20 organizations across four countries, including elite sports and rehabilitation settings. The US wholesale channel is scaling with partners Tobii Dynavox and PRC-Saltillo expanding their reach. In Europe, Control Bionics intends to secure its first German distribution partner soon after gaining HMV insurance coverage. Additionally, the UK market is showing strong demand with multiple agreements signed. In Japan, clinical validation from STROKE LAB has been positive. Overall, the company is focused on turning its commercial groundwork into revenue and reaching key strategic milestones.
Key Points
  • First NextLevel tablets shipped, expected to boost FY27 growth.
  • NeuroStrip expanded to 20 organizations across four countries.
  • US wholesale channel scaling with Tobii Dynavox and PRC-Saltillo.
  • Germany to announce first distribution partner, expanding European presence.
  • UK market visit resulted in multiple agreements and further negotiations.
  • Positive clinical validation from STROKE LAB in Japan.
  • Focused on converting commercial groundwork into revenue.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.